Amgen prepares for EU patent rejig

Amgen brought in Hill & Knowlton for communications advice surrounding the controversial planned changes to European rules on biosimilars.

The hire of H&K befits Amgen's powerful status in the biotech market and highlights its concerns over  new rules for biosimilars – copies of biopharma medicines that can be made after the patent on original products has expired.

It has been speculated by some industry watchers that the European Medicines Agency will grant approval for the first wave of biosimilars this year.

Finalisation of guidelines is expected within the next six months.
Amgen continues to be an H&K client in the US and Portugal. The agency won the European project account following an agency review last year (PRWeek, 5 August 2005).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in